Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results

Arbutus Biopharma Corporation (NASDAQ:ABUS) is one of the 10 Most Profitable Small Cap Stocks to Buy.

On May 13, 2026, Arbutus Biopharma Corporation (NASDAQ:ABUS) reported Q1 2026 revenue of $179.1 million with estimated license revenue tied to its litigation settlement with Moderna. The company said revenue jumped from $1.8 million a year earlier because of the increase in its share of a noncontingent settlement payment through Genevant Sciences.

Arbutus Biopharma Corporation (NASDAQ:ABUS) reported net income of $169.7 million from a $24.5 million loss. The research and development expenses dropped to $4.1 million from $9.0 million with cost reductions and lower trial activity. General and administrative expenses edged higher to $5.9 million due to legal costs, the company added.

Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results

Separately, the firm said the US Food and Drug Administration granted Fast Track designation to imdusiran. It noted that the program could speed up development and review timelines.

The corporation ended the quarter with $95.2 million in cash and investments, making its financial position solid, it said.

Arbutus Biopharma Corporation (NASDAQ:ABUS) is a clinical-stage biopharmaceutical firm. It is involved in developing novel therapeutics that target specific viral diseases.

While we acknowledge the risk and potential of ABUS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABUS and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1